Celia Oreja-Guevara is the Vice Chair of Neurology and Head of Multiple Sclerosis (MS) Center at the University Hospital San Carlos, Madrid, Spain, and an Associate Professor of Neurology at the Complutense University of Madrid, Spain.
Dr Oreja-Guevara received her MD from the Complutense University of Madrid, after which she completed a PhD in neuroimmunology at the Max Planck Institute of Neurobiology, Munich, Germany. She completed her residency at the Ruhr-University Bochum, Bochum, Germany and went on to complete a postdoctoral fellowship in neuroimaging at the San Raffaele Hospital, Milan, Italy. Dr Oreja-Guevara has worked as a Neurologist and later as the Head of the Clinical Neuroimmunology and MS Center of La Paz University Hospital, Madrid, Spain, before she moved to the University Hospital San Carlos to work as the Coordinator of Clinical Research in the MS Unit.
Dr Oreja-Guevara is the Co-Chair of the Scientific Panel on MS and is part of the Teaching Course sub-Committee of the European Academy of Neurology. She is also an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency. In addition, she is a member and past Chair of the Demyelinating Diseases Panel at the Spanish Neurological Society.
Speaking treatments for multiple sclerosis and NMOSD
Dr Oreja-Guevara’s interests lie in improving current treatment strategies for MS and neuromyelitis optica spectrum disorder (NMOSD). She has been involved in a number of clinical trials evaluating new drugs for these conditions. In addition, Dr Oreja-Guevara is also interested in clinical and neuroimaging correlations in MS.
During the COVID-19 pandemic, Dr Oreja-Guevara participated in several studies investigating the impact of COVID-19 infection in patients with MS, as well as the safety of disease modifying therapies during this period.